S&P 500   3,880.30 (-2.35%)
DOW   31,401.24 (-1.50%)
QQQ   283.58 (-3.37%)
AAPL   137.98 (-3.58%)
MSFT   255.06 (-2.14%)
FB   177.30 (-9.65%)
GOOGL   2,070.76 (-7.13%)
AMZN   2,067.06 (-3.91%)
TSLA   636.51 (-5.69%)
NVDA   160.00 (-5.31%)
BABA   82.57 (-5.34%)
NIO   14.69 (-8.19%)
AMD   90.69 (-4.61%)
CGC   4.92 (-5.20%)
MU   66.42 (-4.56%)
T   20.70 (-0.19%)
GE   72.11 (-4.44%)
F   12.30 (-4.13%)
DIS   100.19 (-5.33%)
AMC   10.57 (-8.72%)
PFE   52.92 (+0.08%)
PYPL   77.56 (-4.46%)
NFLX   178.30 (-4.88%)
S&P 500   3,880.30 (-2.35%)
DOW   31,401.24 (-1.50%)
QQQ   283.58 (-3.37%)
AAPL   137.98 (-3.58%)
MSFT   255.06 (-2.14%)
FB   177.30 (-9.65%)
GOOGL   2,070.76 (-7.13%)
AMZN   2,067.06 (-3.91%)
TSLA   636.51 (-5.69%)
NVDA   160.00 (-5.31%)
BABA   82.57 (-5.34%)
NIO   14.69 (-8.19%)
AMD   90.69 (-4.61%)
CGC   4.92 (-5.20%)
MU   66.42 (-4.56%)
T   20.70 (-0.19%)
GE   72.11 (-4.44%)
F   12.30 (-4.13%)
DIS   100.19 (-5.33%)
AMC   10.57 (-8.72%)
PFE   52.92 (+0.08%)
PYPL   77.56 (-4.46%)
NFLX   178.30 (-4.88%)
S&P 500   3,880.30 (-2.35%)
DOW   31,401.24 (-1.50%)
QQQ   283.58 (-3.37%)
AAPL   137.98 (-3.58%)
MSFT   255.06 (-2.14%)
FB   177.30 (-9.65%)
GOOGL   2,070.76 (-7.13%)
AMZN   2,067.06 (-3.91%)
TSLA   636.51 (-5.69%)
NVDA   160.00 (-5.31%)
BABA   82.57 (-5.34%)
NIO   14.69 (-8.19%)
AMD   90.69 (-4.61%)
CGC   4.92 (-5.20%)
MU   66.42 (-4.56%)
T   20.70 (-0.19%)
GE   72.11 (-4.44%)
F   12.30 (-4.13%)
DIS   100.19 (-5.33%)
AMC   10.57 (-8.72%)
PFE   52.92 (+0.08%)
PYPL   77.56 (-4.46%)
NFLX   178.30 (-4.88%)
S&P 500   3,880.30 (-2.35%)
DOW   31,401.24 (-1.50%)
QQQ   283.58 (-3.37%)
AAPL   137.98 (-3.58%)
MSFT   255.06 (-2.14%)
FB   177.30 (-9.65%)
GOOGL   2,070.76 (-7.13%)
AMZN   2,067.06 (-3.91%)
TSLA   636.51 (-5.69%)
NVDA   160.00 (-5.31%)
BABA   82.57 (-5.34%)
NIO   14.69 (-8.19%)
AMD   90.69 (-4.61%)
CGC   4.92 (-5.20%)
MU   66.42 (-4.56%)
T   20.70 (-0.19%)
GE   72.11 (-4.44%)
F   12.30 (-4.13%)
DIS   100.19 (-5.33%)
AMC   10.57 (-8.72%)
PFE   52.92 (+0.08%)
PYPL   77.56 (-4.46%)
NFLX   178.30 (-4.88%)
NASDAQ:VKTX

Viking Therapeutics (VKTX) Stock Forecast, Price & News

$2.17
-0.08 (-3.56%)
(As of 05/24/2022 11:13 AM ET)
Add
Compare
Today's Range
$2.12
$2.24
50-Day Range
$2.20
$3.38
52-Week Range
$2.15
$7.20
Volume
12,818 shs
Average Volume
1.05 million shs
Market Capitalization
$167.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.73
30 days | 90 days | 365 days | Advanced Chart
Receive VKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Viking Therapeutics logo

About Viking Therapeutics

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VKTX
Fax
N/A
Employees
17
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$2.36 per share

Profitability

Net Income
$-54.99 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
73,118,000
Market Cap
$167.90 million
Optionable
Optionable

Company Calendar

Last Earnings
4/27/2022
Today
5/24/2022
Next Earnings (Estimated)
7/27/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.99 out of 5 stars

Medical Sector

608th out of 1,423 stocks

Pharmaceutical Preparations Industry

276th out of 678 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -













Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions

Is Viking Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Viking Therapeutics stock.
View analyst ratings for Viking Therapeutics
or view top-rated stocks.

When is Viking Therapeutics' next earnings date?

Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Viking Therapeutics
.

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics, Inc. (NASDAQ:VKTX) issued its quarterly earnings results on Wednesday, April, 27th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01. During the same period in the prior year, the company posted ($0.19) earnings per share.
View Viking Therapeutics' earnings history
.

What price target have analysts set for VKTX?

7 equities research analysts have issued 12-month price targets for Viking Therapeutics' stock. Their forecasts range from $10.00 to $21.00. On average, they anticipate Viking Therapeutics' share price to reach $15.43 in the next twelve months. This suggests a possible upside of 614.3% from the stock's current price.
View analysts' price targets for Viking Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Viking Therapeutics' key executives?
Viking Therapeutics' management team includes the following people:
  • Dr. Brian Lian Ph.D., Pres, CEO & Director (Age 56, Pay $872k)
  • Mr. Gregory S. Zante, Chief Financial Officer (Age 51, Pay $536k)
  • Ms. Marianne Mancini, Chief Operating Officer (Age 57, Pay $543k)
  • Mr. Michael Morneau, VP of Fin. & Admin. (Age 57)
What other stocks do shareholders of Viking Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.65%), Vanguard Group Inc. (4.76%), Dimensional Fund Advisors LP (1.78%), State Street Corp (1.75%), Renaissance Technologies LLC (1.25%) and Northern Trust Corp (0.84%). Company insiders that own Viking Therapeutics stock include Ligand Pharmaceuticals Inc and Matthew W Foehr.
View institutional ownership trends for Viking Therapeutics
.

Which major investors are selling Viking Therapeutics stock?

VKTX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, UBS Group AG, Northern Trust Corp, PDT Partners LLC, Invesco Ltd., Raymond James Financial Services Advisors Inc., Jane Street Group LLC, and Rhumbline Advisers.
View insider buying and selling activity for Viking Therapeutics
or view top insider-selling stocks.

Which major investors are buying Viking Therapeutics stock?

VKTX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Dimensional Fund Advisors LP, Vanguard Group Inc., Goldman Sachs Group Inc., Connor Clark & Lunn Investment Management Ltd., Walleye Capital LLC, Graham Capital Management L.P., and Bank of New York Mellon Corp.
View insider buying and selling activity for Viking Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Viking Therapeutics?

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viking Therapeutics' stock price today?

One share of VKTX stock can currently be purchased for approximately $2.16.

How much money does Viking Therapeutics make?

Viking Therapeutics has a market capitalization of $167.13 million. The biotechnology company earns $-54.99 million in net income (profit) each year or ($0.740010) on an earnings per share basis.

How many employees does Viking Therapeutics have?

Viking Therapeutics employs 17 workers across the globe.

What is Viking Therapeutics' official website?

The official website for Viking Therapeutics is www.vikingtherapeutics.com.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at (858) 704-4660 or via email at [email protected].

This page was last updated on 5/24/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.